Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEC74647 and HEC110114 Effect on Midazolam PK in Healthy Subjects
NCT05504876Phase 1Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- Nov 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of antaitavir hasophate and encofosbuvir in hepatitis C (HCV), sponsored by Sunshine Lake Pharma. Primary endpoints: Maximum Plasma Concentration at Day 9, Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration at Day 9 and 2 more. Started Nov 2022; status: completed.
02
Drugs
antaitavir hasophateencofosbuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT05504876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05504876.